In the UK alone, 367,000 people are diagnosed with cancer every year. This insight looks at how radiotherapy plans are devised and executed in a clinical setting, and at some of the companies filing patent applications in this area.
Insights: Biotechnology & Pharmaceuticals
We are pleased to introduce our new newsletter, Sustainable Future: Exploring innovations for the Energy Transition and Circular Economy.
This week, we learned that questions relating to the use of post-filed data/evidence to support a technical effect will be referred to the Enlarged Board of Appeal.
In addition to patents, pharmaceuticals and biopharmaceutical companies may achieve drug exclusivity in Europe through SPCs and regulatory data protection. This can exclude competitors and maximise return on substantial research and development investment.
Brazilian IP Law previously provided that the term of a patent is the longest of 20 years from filing date or 10 years from date of grant. This ensures a minimum term of ten years from the grant date; it can be thought of, effectively, as an automatic “Patent Term Adjustment” to account for delays in prosecution by the Brazilian Intellectual Property Office.
A few weeks ago, the Enlarged Board of Appeal of the European Patent Office (EPO) issued a decision on the extent to which computer-implemented simulations are patentable in Europe (previously reported here). The confirmation that computer-implemented simulations should be considered in the same way as any other computer-implemented process could be significant for the industry that filed more European patents than any other in 2020: Medical Technology.
While the United Kingdom’s response to the ongoing COVID-19 pandemic has drawn criticism, there are ways in which the UK has performed well and that perhaps even warrant the accolade “world beating” or, at least, world leading. One of these is the recent success of the vaccine rollout. Another less heralded but equally impressive achievement […]
Supplementary Protection Certificates (SPCs): Could the EU/UK trade deal have an impact on future SPC terms in Europe?
Just over one month into the “real Brexit” we have already seen two very high profile consequences of its impact on the pharmaceutical industry.Firstly, the UK’s medicine agency (the MHRA) approved the BioNTech/Pfizer and Oxford University/Astra Zeneca Covid-19 vaccines faster than the European Medicines Agency (EMA). Then, at the end of January, the European Commission threatened to prevent Covid-19 vaccines passing into Northern Ireland from Ireland. I am certainly not going to explore the potential political ramifications of this (swiftly withdrawn) threat of the EU Commission – twitter commentators have had their say on that – but I am interested in whether this unique situation on the island of Ireland could have future consequences for supplementary protection certificates (SPCs) in the UK and Europe.